

ORIGINAL

Open Access

DFT/NBO study of Nanotube and Calixarene with anti-cancer drug

Karim Zare^{1,2}, Nasim Shadmani^{3*} and Elham Pournamdari⁴

Abstract

Nowadays use of calixarenes and nanotubes are widely spread in the pharmaceutical industry. In this work, interaction of between calix[4]arene and nanotube (6, 6) with Fluorouracil drug are investigated. The DFT calculations have been performed using the Gauss view and Gaussian98 in B3LYP method and 6-31G (d) standard basis set at 298.15K. There are calculated length bond (Å), bond angel (deg), dihedral angel (deg), energy hyperconjugation, and total energy (KJ mol⁻¹), moment dipole (Debye), occupancy between nanotube (6, 6) and calix[4]arene with anticancer drug in B3LYP/6-31G (d) method. These cases and medicines show that complex1 is more stable than complex1. The parameter of E^2 , gap energy and ΔE° in composite of nanotube- Fluorouracil are higher than calix[4]arene-Fluororacil; therefore, complex1 is more stable.

Keyword: Drug delivery; Nanotube; DFT; Fluorouracil; Calix[n]arene; NBO; Capacity heat; Formation energy

Introduction

The application of nanotechnology in disease treatment, diagnosis, monitoring, and in the control of biological systems at the single molecule or molecular assembly level is referred to as nanomedicine. The major goal of nanomedicine is the design of material capable of delivery and targeting of pharmaceutical, therapeutic, and diagnostic agents [1-5]. The type of drug delivery system carbon nanotube discovery by Iijima in 1990s [6]. A nanotube can be thought of as a hexagonal network of carbon atoms that has been rolled up to make seamless cylinder [7,8]. Carbon nanotubes exhibit superior thermal [9], mechanical [10], and electrical properties [11] and are considered the most promising building block for manufacturing low-cost, high-performance nanostructured composite materials [12].

In the paper, complexation of between fluorouracil and nanotube (6,6)/calix[4]arene are investigated as drug delivery system. Calixarenes, crown ether, and cyclodextrin are group of organic macrocyclic agents that have cup like shape which are easily available through the cyclocondensation of para-substituted phenols with formaldehyde [13,14]. One way to increase the aqueous

solubility of drugs is to use complexing agents to form host-guest complexes [15-17]. Calixarenes are promising materials for nanomedicine application in drug delivery systems. For example, hydrophilic derivatives have shown interesting levels of activity against bacteria [19], fungi, cancerous cells and enveloped viruses, but also against thrombosis or fibrosis diseases [10,20-22]. Anti-cancer genes act in a dominant fashion: when ectopically over expressed, they specifically destroy tumor cells without harming normal cells. This cell destruction can come in various modes such as apoptosis, mitotic catastrophe followed by apoptosis or necrosis, and autophagy. Anti-cancer genes have only recently emerged from studies on cancer cells [23-26]. Fluorouracil or 5-Fluoropyrimidin-2,4(1H, 3H)-dione is used as anti-cancer drug. Fluorouracil is an analog of pyrimidine which has been used as an anti-cancer drug for 40 years. The structure of fluorouracil is observed in Figures 1a and 2. It is anti metabolite drug and acts in several ways, but principally as synthesis inhibitor. These days there are ways to deliver a drug in the body without side effects [27]. In this paper, we reported types of drug delivery system such as nanotube and calix[4]arene.

Results and discussion

The several computational tools of, such as Density Functional Theory (DFT), Car-Parrinello molecular dynamics

* Correspondence: n.shadmani@gmail.com

³Young Researchers and Elites Club, Rasht Branch, Islamic Azad University, Rasht, Iran

Full list of author information is available at the end of the article




Figure 1 The structures of optimized (a, b, c, d, e) using B3LYP/6-31G (d) method at 298.15K.




Figure 2 The structure of 5-fluoropyrimidin-2,4(1H,3H)-dione.

simulations, and hybrid QM/MM approaches, can be used for calculations. Density functional quantum chemical calculations have recently provided a relatively consistent picture on base pair interaction energies and geometrics. This can lead to more detailed information on structure, charge distribution, and energetic of the base pair [28-31]. At present, quantum chemical is almost universally applicable to the interpretation of physical and chemical properties of various compounds [32]. Understanding the biochemical mechanism of a disease usually suggests the types of molecules required for new drugs. In all cases, the aim of using the computer for drug design is to analyze the interactions between the drug and receptor sites and to design drugs that give an optimal fit [33-35]. Figure 1 shows the optimized compound calix[4]arene, nanotube (6,6), fluorouracil, nanotube (6,6)-fluorouracil (complex 1), and calix[4]arene-fluorouracil (complex 2) by DFT method in level B3LYP/6-31G (d).

The highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO), [36], the HOMO-LUMO bond gap have been found as a measure of the structural stability properties [37]. The parameters of bond length (Å), natural bond orbital (NBO) and bond angle (deg), dihedral angle (deg),

Table 1 Parameters of in B3LYP/6-31G (d) method optimized by complexes 1 and 2 at 298.15K

| Agent | Complex 1 | Complex 2 |
|--|-----------|-----------|
| $C_{30}-C_{84}/O_{84}$ | 1.47 | 1.40 |
| $C_{30}=C_{20}$ | 1.37 | 1.35 |
| $C_{36}\cdots C_{29}$ | 1.43 | 1.40 |
| $C_{28}-C_{30}$ | 1.47 | 1.46 |
| $C_{85}\cdots N_{87}$ | 1.37 | 1.38 |
| $N_{87}-C_{91}$ | 1.39 | 1.40 |
| $C_{91}=O_{94}$ | 1.22 | 1.23 |
| $C_{30}-C_{28}\cdots C_{27}$ | 116.02 | 121.62 |
| $C_{84}=C_{85}-H_{88}$ | 121.36 | 122.70 |
| $C_{85}\cdots N_{87}-H_{92}$ | 120.82 | 120.48 |
| $N_{87}-C_{91}=O_{94}$ | 123.42 | 123.77 |
| $C_{91}-N_{89}-H_{93}$ | 115.60 | 115.47 |
| $O_{90}=C_{86}-C_{84}$ | 126.90 | 124.39 |
| $C_{30}-C_{84}=C_{85}\cdots N_{87}$ ¹ | 178.86 | - |
| $H_{87}-C_{84}-N_{86}\cdots H_{91}$ ² | 0.79 | 0.52 |
| $C_{90}-N_{88}-C_{85}=O_{89}$ ³ | -178.64 | -179.12 |
| $H_{61}-C_{29}=C_{30}-C_{28}$ ⁴ | 172.74 | - |
| $O_{94}=C_{91}-N_{89}-C_{86}$ ⁵ | 179.16 | 173.95 |
| $C/H_{30}-C_{28}\cdots C_{27}\cdots C_{34}$ ⁶ | -26.01 | 35.84 |

Bond distances (Å), Bond Angles (deg) and dihedral Angles (deg).

1: $C_{30}-C_{84}=C_{85}\cdots N_{87}$ dihedral angles, 2: $H_{87}-C_{84}-N_{86}\cdots H_{91}$ dihedral Angles, 3: $C_{90}-N_{88}-C_{85}=O_{89}$ dihedral Angles, 4: $H_{61}-C_{29}=C_{30}-C_{28}$ dihedral angles, 5: $O_{94}=C_{91}-N_{89}-C_{86}$ dihedral angles, 6: $C/H_{30}-C_{28}\cdots C_{27}\cdots C_{34}$ dihedral angles.

distances of analysed models of the nanotube (6, 6) and calix[4]arene are calculated by DFT at the level of B3LYP and 6-31G (d) standard basis set and are shown in Table 1. The DFT calculated geometric parameters for complex 1, and 2 are compared in Table 1. The bond lengths $C_{30}-C_{84}/O_{84}$ calculated for complex 1, 2 at the DFT level range from 1.47 to 1.40 Å, at the B3LYP/6-31G (d) level.

The bond lengths calculated at $C_{36}\cdots C_{29}$ for complex 1 (in ring nanotube), 1.44 Å and, for complex 2, 1.40 Å, are within the range (in ring calixarene). The bond lengths calculated $C_{85}\cdots N_{87}$ for complex 1, 1.37 Å, and complex 2 are ranged 1.38 Å. The $C_{88}\cdots N_{92}$ bond length is lower than $C_{36}\cdots C_{29}$ bond length in complex 1 and 2. With that reason, there is more electronegativity of nitrogen than carbon.

The angles for $N_{87}-C_{91}=O_{94}$ are 123.41° and 123.77° for complexes 1 and 2. The angles for $C_{84}-C_{86}=O_{90}$ are 126.9° and 124.4° for complex 1, 2. The angles for $C_{84}-C_{86}=O_{90}$ is larger than the angel for $N_{87}-C_{91}=O_{94}$ in complexes 1 and 2. The interaction of between nonbonding and bonding pairs on the nitrogen atom of the angle are reduced in $N_{87}-C_{91}=O_{94}$.

The dihedral angles for $C/H_{30}-C_{28}\cdots C_{27}\cdots C_{34}$ for complex 1 and 2 range from -26.01° to 35.84° (in dihedral 6). The dihedral angles 1,2,3,4,5 and 6, are observed in Table 1 and Figure 3.

The calculations of the total energies, hyperconjugation energy (E^2) of the optimized structures, dipole moments (μ), occupancy and hybrid at B3LYP/6-31G (d) levels are presented in Tables 2 and 3. In Table 2, the Mulliken charges in donor atoms electronegative O_{84} and acceptor




Figure 3 Pole of changed dihedral angel of complexes 1, and 2 using method B3LYP/6-31G (d) at 298.15 K.

Table 2 The NBO parameters of, Complex 1 and 2 are calculated in B3LYP/6-31G (d) method at 298.15K

| Agent | Donor | Occupancy | Acceptor | Occupancy | hybrid | E ² | Σ E ² |
|----------|---------------|-----------|---------------|-----------|---------------------|----------------|------------------|
| Complex1 | BD(1)C30- C84 | 1.96631 | BD*(1)C27-C28 | 0.02586 | Sp ^{1.98} | 1.48 | 35.53 |
| | | | BD*(1)C28-C30 | 0.02920 | Sp ^{2.06} | 1.70 | |
| | | | BD*(1)C29-C30 | 0.02033 | Sp ^{1.79} | 3.12 | |
| | | | BD*(1)C29-C36 | 0.02164 | Sp ^{1.96} | 2.51 | |
| | | | BD*(1)C84-C85 | 0.01852 | Sp ^{1.88} | 3.55 | |
| | | | BD*(1)C84-C86 | 0.06682 | Sp ^{2.28} | 1.82 | |
| | | | BD*(1)C85-N87 | 0.01939 | Sp ^{2.51} | 3.76 | |
| Complex2 | BD*(2)C84-C85 | 0.23733 | BD*(2)C29-C3 | 0.2195 | Sp ^{99.99} | 17.59 | 22.77 |
| | BD(1)C28-O32 | 1.94416 | BD*(1)C4-C5 | 0.0219 | Sp ^{1.9} | 1.48 | |
| | | | BD*(1)C15-C27 | 0.02108 | Sp ^{1.85} | 1.6 | |
| | | | BD*(1)C60-C64 | 0.07182 | Sp ^{1.71} | 1.93 | |
| | | | BD*(2)C62-C64 | 0.24487 | Sp ^{1.00} | 0.66 | |
| | LP(1)O32 | 1.93171 | BD*(1)C4-C28 | 0.03327 | Sp ^{1.98} | 1.88 | |
| | | | BD*(2)C27-C28 | 0.37632 | Sp ^{1.00} | 5.18 | |
| | | | BD*(1)C4-C28 | 0.03327 | Sp ^{1.98} | 3.86 | |
| | LP(2)O32 | 1.87683 | BD*(1)27-C28 | 0.03258 | Sp ^{1.95} | 6.15 | |

C₃₀ are negative and positive, respectively. Complex 1 has gap of energy that is larger than complex 2; therefore, complex 1 is stable. In Table 2, it becomes obvious that the complex 1 has formed higher hyperconjugation energy than complex 2. Also, the results show that by increasing P part in hybrid of atoms, the occupancy decreases. The S orbital part in hybrid of carbon in complex 2 is more than the S orbital part in hybrid of in complex 1. Combined with the most of hyperconjugation energy is stable. The occupancy coefficient is smaller. Complex 1 is more stable than the complex 2. The hyperconjugation energy complex 1 at 37.34 is larger than that in complex 2. The hybrid orbital S of a compound is lower. Table 2 shows the HOMO and LUMO energies for complexes. By evaluating HOMO/LUMO gap energies, it is obvious that if the gap becomes bigger, the complex will be stable; therefore, complex 1 is more stable than the complexes. The results of the present work were obtained using DFT optimization and formation energy (ΔE_f° in KJmol⁻¹) calculation at the B3LYP/6-31G (d) level. ΔE_f° is calculated using the formula $\Sigma E^\circ_{\text{product}} - \Sigma E^\circ_{\text{reactant}}$. ΔE_f° values in complexes 1 and 2 are in the range of -13.275 and +46.902 KJmol⁻¹; therefore, complex1 has lower formation energy than the others. The energy (kJ mol⁻¹) and dipole moments (Debye) indicate the consistency

between the two complex calculations in DFT method. The gap energies and total energy, ΣE^2 , HOMO and LUMO complexes 1, 2 were calculated using the B3LYP method and 6-31G (d) basis set. The total energy sum of energy transitional, energy rotational and energy vibration in level B3LYP/6-31G (d) for complexes 1, 2 was calculated. The obtained results are shown in Table 3.

Heat capacity is the measurable physical quantity that specifies the amount of heat required to change the temperature of body by a given amount. Translation, rotation, and a combination of the two types of energy in vibration (kinetic and potential) of atoms represent the degrees of freedom of motion which classically contribute to the heat capacity of matter, but loosely bound electrons may also participate. On a microscopic scale, each system particle absorbs thermal energy among the few degrees of freedom available to it, and at sufficient temperatures, this process contributes to the specific heat capacity that classically approaches a value per mole of particles that is set by the Dulong-Petit law. For quantum mechanical reasons, at any given temperature, some of these degrees of freedom may be unavailable, or only partially available, to store thermal energy. Quantum theory can be used to quantitatively predict the specific heat capacity of simple systems.

Table 3 Formation energy, total energy, HOMO, LUMO, Gap of energy, moment dipole and heat capacity are calculated in B3LYP/6-31G (d) method at 298.15 K


| Agent | E _{total} | ΔE _f ^o | HOMO | LUMO | Gap | μ | C _v |
|-----------|--------------------|------------------------------|----------|----------|----------|-------|----------------|
| Complex 1 | 465.73 | -13.275 | -0.15877 | -0.08918 | -0.0696 | 0.527 | 191.03 |
| Complex 2 | 348.03 | +46.902 | -0.19989 | -0.05481 | -0.14508 | 0.591 | 130.52 |

Conclusions

In this paper, the result shows that complex 1 between Nanotube (6,6) and fluorouracil is more stable than complex 2. Thus, complex 1 is a better conditioner for drugs than complex 2. NBO analysis shows larger gap energy in complex 1. Complex 1 has lower formation energy and is more stable than complex 2.

Methods

Investigation is carried out using a personal computer (Intel (R) Pentium (R) dual CPU with 2GB RAM). Nanotube-fluorouracilarene (with different atom number) which reacts with anti-cancer drug. In this paper, the drug delivery properties are investigated by NBO analysis and DFT method. The DFT calculations have been performed using the Nanotube modeler [38], Gaussview [39] and Gaussian 03 [40] using B3LYP method and 6-31G (*d*) standard basis set. NBO analysis [41,42] calculations have been also performed for all composites using B3LYP method and the standard 6-31G (*d*) basis set. Complexes between calix[4]arenes and nanotube (6,6) with Fluorouracil drug are optimized, then bond length (Å), bond angle (deg), dihedral angle (deg), hyperconjugation energy, as well as total energy (KJmol⁻¹), moment dipole (Debye), occupancy, total energy and HOMO/LUMO are investigated between nanotube (6, 6) and calix[4]arene with anti-cancer drug using B3LYP/6-31G (*d*) method. Nanotube/calix[4]arenes and fluorouracil reaction are shown in Equations 1 and 2.



Competing interests

The authors declare that they have no competing interests.

Authors' contributions

KZ and NSH both contributed to this research work. Both authors read and approved the final manuscript.

Acknowledgements

Both of authors are grateful to University of Science and Research Branch, Islamic Azad University, Tehran, Iran. We are grateful to Shahid Beheshti University, Tehran, Iran. We are grateful to Young Researchers and Elites Club, Rasht Branch, Islamic Azad University, Rasht, Iran for financial support.

Author details

¹Department of Chemistry, Science and Research Branch, Islamic Azad University, Tehran, Iran. ²Department of Chemistry, Shahid Beheshti University, Evin, Tehran, Iran. ³Young Researchers and Elites Club, Rasht

Branch, Islamic Azad University, Rasht, Iran. ⁴Department of Chemistry, Islamshahr Branch, Islamic Azad University, Islamshahr, Iran.

Received: 9 June 2013 Accepted: 11 July 2013

Published: 03 Sep 2013

References

1. Wong Shi Kam, N, Jessop, TC, Wender, PA, Dai, H: Nanotube molecular transporters: Internalization of carbon nanotube-protein conjugates into mammalian cells. *J. Am. Chem. Soc.* **126**, 6850–6851 (2004)
2. Colomer, JF, Henrard, L, Lambin, P, Van Tendeloo, G: 2001. *Phys. Rev. B* **64**, 1–7 (2001)
3. Moradi, O, Zare, K: Adsorption of Pb(II), Cd(II) and Cu(II) Ions in Aqueous Solution on SWCNTs and SWCNT-COOH Surfaces: Kinetics Studies. *Fullerenes, Nanotubes, and Carbon Nanostructures* **19**, 628–652 (2011)
4. Pouton, CW, Seymour, L: Key issues in non-viral gene delivery. *Adv. Drug. Deliv. Rev.* **46**, 187–203 (2001)
5. Singh, R, Pantarotto, D, Lacerda, L, Pastorin, G, Klumpp, C, Prato, M, Bianco, A, Kostarelos, K: Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 3357–3362 (2006)
6. Iijima, S: Helical microtubules of graphitic carbon. *Nature* **354**, 56–58 (1991)
7. Yan, CS, Mao, HK, Li, W, Qian, J, Zhao, Y, Hemley, RJ: Ultrahard diamond single crystals from chemical vapor deposition. *Physica Status Solidi (A)* **201**(4), 25–27 (2004)
8. Kalele, S, Gosavi, SW, Urban, J, Kulkarni, SK: Nanoshell particles: synthesis, properties and applications. *Curr. Sci.* **91**, 8 (2006)
9. Wong Shi Kam, N, Jessop, TC, Wender, PA, Dai, H: Nanotube molecular transporters: Internalization of carbon nanotube-protein conjugates into mammalian cells. *J. Am. Chem. Soc.* **126**, 6850–6851 (2004)
10. Pastorin, G: Crucial Functionalizations of Carbon Nanotubes for Improved Drug Delivery: A Valuable Option? *Pharmaceut. Res.* **26**, 746–769 (2009)
11. Taft, BJ, Lazareck, AD, Withey, GD, Yin, A, Xu, JM, Kelley, SO: Site-specific 258 assembly of DNA and appended cargo on arrayed carbon nanotubes. *J. Am. Chem. Soc.* **126**, 12750–12751 (2004)
12. Pantarotto, D, Singh, R, McCarthy, D, Erhardt, M, Briand, JP, Prato, M, Kostarelos, K, Bianco, A: Functionalized carbon nanotubes for plasmid DNA 262 gene delivery. *Angew. Chem. Int. Ed.* **43**, 5242–5236 (2004)
13. Asfari, Z, Böhmer, V, Harrowfield, J, Vicens, J: *Calixarenes 2001*. ED; Kluwer, Dordrecht (2001)
14. Gungor, O, Memon, S, Yilmaz, M: Synthesis of Alkyl Nitrile and Alkyl Benzonitrile Derivatives of Calix[4]Arene and Their Polymer Supported Analogues: A Comparative Study in Two-Phase Extraction Systems. *J. Funct. Polym.* **63**, 1–9 (2005)
15. Gutsche, CD, Bauer, LJ: The conformational properties of calix[4]arenes, calix[6]arenes, calix[8]arenes, and oxacalixarenes. *J. Am. Chem. Soc.* **107**, 6052–6059 (1985)
16. Faraji, M, Zare, K, Aghaei, H, Farajtabar, A, Asfari, Z, Gharib, F: Complexation of p-Sulphonato-calix[6]arene by Glycine, Glycyl-glycine, and Glycyl-glycyl-glycine in Aqueous Solution. *J. Solution. Chem.* (2012). doi:10.1007/s10953-012-9924-2
17. Gharib, F, Zare, K, Taghvai, S, Monajjemi, M, Amiri, A: Complexation of tri-*n*-propyl-p-*t*-butyl calix[4]arene with alkali metal cations in carbon tetrachloride solvent. *Main. Group. Met. Chem.* **26**, 255–258 (2003)
18. Gharib, F, Zare, K, Amiri, A: Spectrophotometric studies of alkali metal ion complexes of p-tetrabutyl-calix[4]arenes. *Russ. J. Inorg. Chem.* **49**, 1511–1514 (2004)
19. Gharib, F, Osouledini, N, Zare, K, Taghvai-Ganjali, S: Spectrophotometric studies of alkali and alkali earth metal ions complexes of mono amino derivative of calix[4]arene. *Russ. J. Inorg. Chem.* **55**, 434–437 (2010)
20. Brunink, JAJ, Verboom, W, Engbersen, JFJ, Reinhoudt, DN, Harkema, S: Synthesis and cation complexation selectivity of bis (syn-proximally) functionalized calix[4]arenes. *Recl. Trav. Chim. Pays-Bas* **111**, 511–516 (1992)
21. Shirakawa, S, Shimizu, S: Dehydrative amination of alcohols in water using a water-soluble calix[4]resorcinarene sulfonic acid. *Syn. Lett.* **10**, 1539–1542 (2008)
22. Liu, YL, Liu, L, Wang, YL, Han, YC, Wang, D, Chen, YJ: Calix[*n*]arene sulfonic acids bearing pendant aliphatic chains as recyclable surfactant-type Brønsted acid catalysts for allylic alkylation with allyl alcohols in water. *Green. Chem.* **10**, 635–640 (2008)

23. Zhang, YJ, Cao, WX, Xu: Interaction of Sulfonated Calix[n]arenes with Rhodamine B and Its Application to Determine Acetylcholine in a Real Neutral Aqueous Medium. *J. Chin. Chem.* **20**, 322–326 (2002)
24. Dolg, M: Recent progress in understanding chemical shifts. *J. Chem. Phys.* **115**, 7348–7355 (2009)
25. de Dios, AC, Oldfield, E: Antimalarial drugs and heme in detergent micelles: an NMR study. *Solid State NMR* **6**, 101–125 (1996)
26. Whitehead, RP, Benedetti, JK, Abbruzzese, JL, Ardan, B, Goodwin, JW, Balcerzak, SP, Samlowski, WE, Lenz, H-Z, Macdonald, JS: A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study. *Inves. New. Drug.* **22**, 335–341 (2004)
27. Cornell, GN, Cahow, CE, Frey, C, McSherry, C, Beal, JM: Clinical experience with 5-fluorouracil (NSC-19 893) in the treatment of malignant disease. *Cancer Chemother. Rep.* **9**, 23–30 (1960)
28. Monajjemi, M, Chahkandi, B, Zare, K, Amiri, A: Study of the hydrogen bond in different orientations of adenine-thymine base pairs: an ab initio study. *Biochem* **70**, 366–76 (2005)
29. Guo, D, Liu, Y: Calixarene-based supramolecular polymerization in solution. *Chem. Soc. Rev.* **41**, 5907–5921 (2012)
30. Tirado-Rives, J, Jorgensen, WL: Performance of B3LYP Density Functional Methods for a Large Set of Organic Molecules. *J. Chem. Theory. Comput.* **4**, 297–306 (2008)
31. Zeevaert, JG, Wang, L, Thakur, W, Leung, CS, Tirado-Rives, J, Bailey, CM, Domaal, RA, Anderson, KS, Jorgensen, WL: Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations. *J. Am. Chem. Soc.* **130**, 9492–9499 (2008)
32. Casabianca, LB, Kallgren, JB, Natarajan, JK, Alumasa, JN, Roepe, PD, Wolf, C, de Dios, AC: Antimalarial drugs and heme in detergent micelles: An NMR study. *Inorg. J. Biochem.* **103**, 745–748 (2009)
33. Abul Haider Shipar, M: DFT Studies on Fructose and Glycine Maillard Reaction: Formation of the Heyns Rearrangement Products in the Initial Stage. *J. Iran. Chem. Soc.* **8**, 433–448 (2011)
34. Delchev, VB: Computational (DFT and TD DFT) study of the electron structure of the tautomers/conformers of uridine and deoxyuridine and the processes of intramolecular proton transfers. *J. Mol. Model.* **16**, 749–757 (2010)
35. Ramachandran, KI, Deepa, G, Namboori, K: Research on computational chemistry and molecular modeling. In: *Computational Chemistry and 344 Molecular Modeling: Principles and Applications*, pp. 297–310. Springer, Heidelberg (2008)
36. Miehlich, B, Savin, A, Stoll, H, Preuss, H: Results obtained with the correlation energy density functionals of Becke and Lee–Yang and Parr. *Chem. Phys. Lett.* **157**, 200–206 (1989)
37. Dalili, N, Zare, K, Gharib, F, Shadmani, N: Calixarenes or Nanotubes: Which are better in drug delivery? *JNSC* **2**, 213–217 (2011)
38. www.jcrystal.com/products/wincnt/Nanotube. Nanotube Modeler. version 1.2.4 (2004–2005)
39. Frisch, A, Nielsen, AB, Holder, AJ: *GaussView User Manual*. Gaussian Inc., Wallingford (2000)
40. Frisch, MJ, Trucks, GW, Schlegel, HB, Scuseria, GE, Robb, MA, Cheeseman, JR, Zakrzewski, VG, Montgomery, JA, Stratmann, RE, Burant, JC, Dapprich, S, Millam, JM, Daniels, AD, Kudin, KN, Strain, MC, Farkas, O, Tomasi, J, Barone, V, Cossi, M, Cammi, R, Mennucci, B, Pomelli, C, Adamo, C, Clifford, S, Ochterski, J, Petersson, GA, Ayala, PY, Cui, Q, Morokuma, K, Malick, DK, et al: *GAUSSIAN 03*, revision B.02. Gaussian Inc, Pittsburgh, PA (2003)
41. Glendening, ED, Reed, AE, Carpenter, JE, Weinhold, F: *NBO version 3.1*. Gaussian Inc, Pittsburgh, PA (2003)
42. Fernandez, L, Viruela-Martin, P, Latorre, J, Guillem, C, Beltrán, A, Amorós, P: Molecular precursors of mesostructured silica materials in the atrane route: A DFT/GIAO/NBO theoretical study. *J. Mol. Struct.: THEOCHEM* **822**, 89–102 (2007)

10.1186/2193-8865-3-75

Cite this article as: Zare et al.: DFT/NBO study of Nanotube and Calixarene with anti-cancer drug. *Journal Of Nanostructure in Chemistry* 2013, **3**:75

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com